Gilead Sciences Inc. (GILD)
-NasdaqGS 56.47 
0.73(1.31%) 4:00PM EDT|After Hours
:
56.84 0.37 (0.66%) 7:00PM EDT - Nasdaq Real Time Price
| Prev Close: | 55.74 |
|---|
| Open: | 56.19 |
|---|
| Bid: | 56.83 x 200 |
|---|
| Ask: | 56.84 x 100 |
|---|
| 1y Target Est: | 63.88 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 55.76 - 56.85 |
|---|
| 52wk Range: | 24.12 - 57.10 |
|---|
| Volume: | 10,087,474 |
|---|
| Avg Vol (3m): | 11,822,400 |
|---|
| Market Cap: | 86.14B |
|---|
| P/E (ttm): | 31.62 |
|---|
| EPS (ttm): | 1.79 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Featured on Yahoo! Finance
Headlines
- [$$] A Sampling of "High-Conviction" Stocks and Other Namesat Barrons.com(Tue 6:29PM EDT)
- Gilead's sofosbuvir gets EMA validation, now under assessmentat theflyonthewall.com(Tue 4:51PM EDT)
- InPlay: Gilead Sciences: European Medicines Agency validates Gilead's Marketing Application for sofosbuvir for the treatment of Hepatitis CBriefing.com(Tue 4:30PM EDT)
- European Medicines Agency Validates Gilead’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis CBusiness Wire(Tue 4:30PM EDT)
- Roche, Reloadedat Investopedia(Tue 3:05PM EDT)
- Wall Street Transcript Interview with David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.: Opportunities in Hepatitis C and Genomic TechnologiesWall Street Transcript(Tue 2:22PM EDT)
- Midday Glance: Biotechnology companiesAP(Tue 1:16PM EDT)
- Cramer: Buy Gilead Sciences, General Mills, Genworth Financial, and These 2 Stocksat Wall St. Cheat Sheet(Tue 11:10AM EDT)
- Early Glance: Biotechnology companiesAP(Tue 10:36AM EDT)
- Will Influenza A H7N9 Generate Opportunities For Pharma?at Seeking Alpha(Tue 9:10AM EDT)
- Cramer's Top Stock Picks: SAVE GILD BMY HTA TSLAat TheStreet(Tue 6:00AM EDT)
- Cramer's Watch List Ahead of Big Cancer Conferenceat CNBC(Mon, May 20)
- [video] The War Against Cancerat CNBC(Mon, May 20)
- Final Glance: Biotechnology companiesAP(Mon, May 20)
- 3 Upgrades on Friday Worth Notingat Motley Fool(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 19.47 |
|---|
| P/S (ttm): | 8.54 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.98 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.49 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 1.13 |
|---|
Business Summary
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia.
View More